Arsenic in a Resettlement Scheme: Disclosure Under a Funder's Consent Clause
You are the senior chemist in a state water laboratory. A survey of tube wells in a resettlement scheme returns arsenic of 0.061 and 0.058 mg/L in two wells serving roughly 300 families; a third well reads 0.004 mg/L. The national guideline is 0.010 mg/L. Each well was analysed once; the batch included a certified reference material that read 0.048 mg/L against a certified 0.050 mg/L, but no matrix spike and no duplicate were run. The survey is funded by a company holding the regional fertilizer import licence, and the contract requires the funder's written consent before any project data are released. Your Director instructs you to hold the report until after resampling and after the provincial election in six weeks. A journalist has asked for the well list. A private laboratory in another district, using a field kit, has told the community there is no arsenic problem.
1. Set out your obligations and your immediate actions, including what you put to the Director in writing.
Read the worked answer
Obligations in tension. You have a contractual duty to the funder, an employment duty to the Director, a professional duty to scientific integrity, and a public-health duty to 300 families. They do not rank equally. When a credible finding indicates a health risk, the duty to warn dominates; confidentiality and institutional convenience do not license delay where harm is imminent and preventable.
Is the finding credible enough to act on? A result six times the guideline, with 96% CRM recovery, is credible enough for interim advice even though it is single and unspiked. Waiting for perfect data is itself a decision, and here it is a decision to let people drink the water.
Immediate actions
- Request confirmatory analysis at once: resample both wells with chain of custody, run matrix spikes, duplicates, and arsenic speciation; add a second method if available.
- Send an interim advisory to the health office today: avoid the two wells for drinking and cooking, use the 0.004 mg/L well and tankered supply, do not rely on the field-kit result.
- Put a memo to the Director in writing: the interim advice is issued on public-health grounds, the election timing is not a valid reason for delay, and you are recording the instruction. Ask for a written decision if the instruction is repeated.
- If refused, escalate to the Chief Government Analyst or the professional body, and keep a dated record of every step.
What not to do. Do not go to the journalist first. Internal escalation is the correct sequence; external disclosure becomes defensible only after it fails, or where harm is immediate.
2. How do you reconcile the funder's consent clause with your duty to report, and exactly what would you release?
Read the worked answer
The clause is not a veto. A confidentiality clause can protect commercial information and unpublished data, but it cannot be read as authorising the suppression of a public-health finding; a term used for that purpose would be vulnerable as contrary to public policy. Read it as requiring notice and confidentiality of commercially sensitive material, not as requiring permission to protect health.
Procedure
- Notify the funder in writing of the finding and of the intended release, with a short deadline for comment on commercial content only.
- Seek the Director's approval and, if the funder objects, ask for legal advice through the institution rather than deciding alone.
- Declare the funding relationship and the consent clause in the report itself, so no reader can later say the conflict was hidden.
Release the minimum necessary
- Well identifiers or locations, arsenic concentrations, sampling date, method and its uncertainty, and the applicable guideline.
- A plain statement of what is not yet known: single determinations, no speciation, confirmation pending.
- Public-health advice, in the language of the users.
Withhold only what is genuinely commercial - contract values, internal cost data, proprietary survey design - and say plainly in the release note that this is what has been withheld and why. Selective silence is the thing to avoid; selective detail is legitimate.
3. The confirmatory resample returns 0.059 and 0.055 mg/L with 98% spike recovery, and speciation shows most of it is As(III). What should the laboratory now do, and how should the risk be communicated?
Read the worked answer
Interpretation. The confirmation removes the main technical objection: two independent determinations, good spike recovery, and As(III) dominance. As(III) is the more toxic and more mobile form, which raises rather than lowers concern. The 0.004 mg/L well remains usable; the other two are roughly 5.5–5.9 times the guideline and require a sustained response, not a resample loop.
Laboratory actions
- Issue the final report with full QA attached: CRM, spikes, duplicates, speciation, chain of custody, uncertainty statement, and the fact that the earlier field-kit result was not validated.
- Recommend source investigation, not just well closure: check whether the arsenic is geological or linked to the fertilizer and irrigation regime, since that determines whether new wells will also be affected.
- Set a monitoring schedule with a defined trigger for reclassification, and inform the plant quarantine or public health authority as required.
Communication with 300 families
- Give numbers, not adjectives: 'this water contains about six times the safe level; do not use it for drinking, cooking or making formula'.
- Pair every warning with an immediate alternative - the safe well, tanker schedule, treatment option, and who to contact.
- Avoid both minimisation and alarm: state that arsenic harms health over months and years of exposure, not from a single glass, which is true and reduces panic while preserving urgency.
- Correct the earlier 'no arsenic' message explicitly and name who is correcting it. Communities forgive bad news far more readily than they forgive being misled.